MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce the appointment of healthcare industry executive Damon Goodwin as Global Director of Sales, effective immediately. Mr. Goodwin will play an integral part in MedX’s revenue growth by building global partnerships for MedX’s skin assessment telemedicine technology. Initially supporting the roll out and expansions in Mexico, Brazil and the USA, he will also be responsible for securing joint ventures & partnerships around the world.
“Damon brings years of experience in scaling revenue and building partnerships, the skill sets required as MedX enters an accelerated growth phase, and we are confident he will be able to assist us in driving sales for this next stage of our rapid growth,” said Scott Spearn, CEO of MedX. With our recent funding completed, we now have the opportunity to aggressively pursue markets, both locally and around the world, and we are excited to have him on board as we strengthen our team.”
Mr. Goodwin’s career has spanned many years in the healthcare industry, including roles with pharmaceutical companies in business strategy, international product licensing, business development and operations. He has proven expertise in leading companies through start-up to rapid growth, expansion and value creation at companies such as Biovail, Organon, Boehringer Ingelheim and Aspen Pharmacare.
“This ground-breaking technology that allows Dermatologists to remotely triage potentially lethal lesions will not only help save lives, it can dramatically improve healthcare system capacity,” noted Mr. Goodwin. “It’s an exciting time to be involved and I’m thrilled to be in this new role.”
Currently, between two and three million non-melanoma skin cancers and 300,000 melanoma skin cancers occur globally each year. One in every three cancers diagnosed is a skin cancer and, according to Skin Cancer Foundation Statistics, one in every five people will develop skin cancer in their lifetime. The global demand for SIAscopy on DermSecure™ will continue to increase with the growth of telemedicine and as early detection is recognized as the way to optimize survival and reduce healthcare costs.
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.